NCT00430534View on ClinicalTrials.gov

Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

Not specified

Conditions
Epstein Barr Virus (EBV) Infection
Interventions
BIOLOGICAL

EBV vaccine (268664)

Trial Locations (1)

1200

GSK Clinical Trials Call Center, Brussels

Sponsors

Lead Sponsor

Henogen
All Listed Sponsors
lead

Henogen

INDUSTRY